Literature DB >> 15980977

Temozolomide-induced partial response in a patient with primary diffuse leptomeningeal gliomatosis.

Enrico Franceschi1, Giovanna Cavallo, Luciano Scopece, Roberta Degli Esposti, Gabriele Paioli, Anna Paioli, Emanuela Palmerini, Maria Pia Foschini, Anna Federica Marliani, Lucio Crinò.   

Abstract

Herein we describe the case of a patient with primary diffuse leptomeningeal gliomatosis (PDLG). After surgery and ventriculoperitoneal shunt placement, due to poor general conditions, the patient was not eligible for radiotherapy. For this reason we decided to start a systemic chemotherapy treatment with Temozolomide (150 mg/m2 per day for 5 days every 4 weeks). After three cycles a partial response was achieved with a clear improvement of general conditions. In our knowledge, this is the first time that PDLG treatment with Temozolomide has been described.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15980977     DOI: 10.1007/s11060-004-5672-5

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  10 in total

1.  Primary multifocal leptomeningeal gliomatosis.

Authors:  E Y Tsui; K T Loo; C K Mok; M K Yuen; Y K Cheung
Journal:  Eur J Radiol       Date:  2001-01       Impact factor: 3.528

2.  Primary diffuse leptomeningeal gliomatosis.

Authors:  L A Corsten; A I Raja; F C Wagner
Journal:  Br J Neurosurg       Date:  2001-02       Impact factor: 1.596

3.  Primary diffuse leptomeningeal gliomatosis: unusual MRI with non-enhancing nodular lesions on the cerebellar surface and spinal leptomeningeal enhancement.

Authors:  S Kastenbauer; A Danek; W Klein; T A Yousry; K Bise; G Reifenberger; H W Pfister
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-09       Impact factor: 10.154

4.  Oligodendrogliomatosis with intracranial hypertension.

Authors:  J KOREIN; I FEIGIN; M F SHAPIRO
Journal:  Neurology       Date:  1957-08       Impact factor: 9.910

5.  Heterotopic glial nests in the subarachnoid space; histopathologic characteristics, mode of origin and relation to meningeal gliomas.

Authors:  I S COOPER; J W KERNOHAN
Journal:  J Neuropathol Exp Neurol       Date:  1951-01       Impact factor: 3.685

6.  Survival of patients with high grade glioma treated with intrathecal thiotriethylenephosphoramide for ependymal or leptomeningeal gliomatosis.

Authors:  T F Witham; M B Fukui; C C Meltzer; R Burns; D Kondziolka; M E Bozik
Journal:  Cancer       Date:  1999-10-01       Impact factor: 6.860

7.  Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.

Authors:  W K Yung; M D Prados; R Yaya-Tur; S S Rosenfeld; M Brada; H S Friedman; R Albright; J Olson; S M Chang; A M O'Neill; A H Friedman; J Bruner; N Yue; M Dugan; S Zaknoen; V A Levin
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

Review 8.  Aggressive treatment with complete remission in primary diffuse leptomeningeal gliomatosis--a case report.

Authors:  P Beauchesne; J Pialat; R Duthel; F G Barral; G Clavreul; T Schmitt; B Laurent
Journal:  J Neurooncol       Date:  1998-04       Impact factor: 4.130

9.  Primary diffuse leptomeningeal gliomatosis predominantly affecting the spinal cord: case report and review of the literature.

Authors:  A Baborie; E M Dunn; L R Bridges; J M Bamford
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-02       Impact factor: 10.154

10.  A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.

Authors:  W K Yung; R E Albright; J Olson; R Fredericks; K Fink; M D Prados; M Brada; A Spence; R J Hohl; W Shapiro; M Glantz; H Greenberg; R G Selker; N A Vick; R Rampling; H Friedman; P Phillips; J Bruner; N Yue; D Osoba; S Zaknoen; V A Levin
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

  10 in total
  8 in total

1.  A case report and review of the literature.

Authors:  Shoji Yomo; Tsuyoshi Tada; Shuichi Hirayama; Naoko Tachibana; Masako Otani; Yuichiro Tanaka; Kazuhiro Hongo
Journal:  J Neurooncol       Date:  2006-09-20       Impact factor: 4.130

2.  Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors.

Authors:  Pedro Pérez Segura; Miguel Gil; Carmen Balañá; Ignacio Chacón; José Muñoz Langa; María Martín; Jordi Bruna
Journal:  J Neurooncol       Date:  2012-05-20       Impact factor: 4.130

3.  A case of primary leptomeningeal gliomatosis confined to the spinal cord.

Authors:  Robin Bhatia; Federico Roncaroli; Piers Thomas; Shie-Lee Cheah; Amrish Mehta; Mark Glaser; Christian Ulbricht
Journal:  J Neurooncol       Date:  2009-11-08       Impact factor: 4.130

4.  Primary diffuse leptomeningeal gliosarcomatosis.

Authors:  Yosuke Watanabe; Takuhiro Hotta; Hiroyuki Yoshioka; Yoko Itou; Kiyomi Taniyama; Kazuhiko Sugiyama
Journal:  J Neurooncol       Date:  2007-07-13       Impact factor: 4.506

5.  Long survival of primary diffuse leptomeningeal gliomatosis following radiotherapy and temozolomide: case report and literature review.

Authors:  Niels Hansen; A Wittig; J Hense; O Kastrup; E R Gizewski; J A P Van de Nes
Journal:  Eur J Med Res       Date:  2011-09-12       Impact factor: 2.175

6.  Primary diffuse leptomeningeal oligodendrogliomatosis: A case report and literature review.

Authors:  Amarnath Chellathurai; Jay S Vaidya; Gopinathan Kathirvelu; Periakaruppan Alagappan
Journal:  Indian J Radiol Imaging       Date:  2016 Jul-Sep

7.  Response of Leptomeningeal Dissemination of Anaplastic Glioma to Temozolomide: Experience of Two Cases.

Authors:  Jin Woo Bae; Eun Kyung Hong; Ho-Shin Gwak
Journal:  Brain Tumor Res Treat       Date:  2017-10-31

8.  Primary diffuse leptomeningeal gliomatosis as a rare cause of pain in cervical spine.

Authors:  Štefan Sivák; Ema Kantorová; Egon Kurča; Juraj Marcinek; Pavol Slávik; Jozef Michalik; Vladimír Nosáľ
Journal:  BMC Cancer       Date:  2016-03-04       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.